Takeaways:

  • EBR Systems has secured TGA Priority Review Determination for the wireless WiSE CRT system.
  • The Priority Review shortens evaluation from 225 working days to approximately 150 working days.
  • EBR lodged its TGA submission on 12 March 2026.
  • The WiSE system targets the approximately 40 per cent of heart failure patients who don’t respond to conventional CRT.
  • The TGA milestone follows FDA approval of WiSE in April 2025 and early US commercial activity.

EBR Systems (ASX:EBR) has reached an important regulatory milestone in its Australian commercialisation pathway, securing Priority Review Determination from the Therapeutic Goods Administration (TGA) for its wireless WiSE cardiac resynchronisation therapy (CRT) system. The decision shortens the expected evaluation period from the standard 225 working days to approximately 150 working days, accelerating the timeline to Australian Register of Therapeutic Goods (ARTG) inclusion.

EBR lodged its submission with the TGA on 12 March 2026 and intends to submit its ARTG inclusion application in the near term. Approval is expected to support earlier patient access in Australia for heart failure patients who have not benefited from conventional lead-based cardiac resynchronisation therapy.

Addressing the CRT non-responder population

Approximately 40 per cent of patients with heart failure don’t respond to traditional cardiac resynchronisation therapy, primarily because the leads — the wires delivering electrical pulses — cannot reach the optimal location in the heart. The WiSE system is a wireless cardiac pacing technology designed specifically to treat this CRT non-responder population, providing an alternative pathway for patients with limited treatment Options.

The clinical and commercial opportunity is significant. CRT non-responders represent a large global patient cohort with substantial unmet need, and a successful wireless solution provides both clinical benefit for patients and a clear commercial market for the technology.

Building on FDA approval

The TGA milestone adds to a period of regulatory and commercial progress for EBR Systems following FDA approval of the WiSE system in April 2025. US commercial activity has been progressing through the early phase, with implant volumes building and Revenue beginning to flow.

The combination of FDA approval and pending TGA inclusion positions EBR Systems with two of the world’s most consequential regulatory frameworks. The European pathway represents another potential expansion avenue, with the WiSE system’s clinical evidence base supporting future regulatory engagement across additional geographies.

Why TGA Priority Review matters

TGA Priority Review is reserved for medical devices and products that address significant unmet medical need. The framework provides accelerated evaluation while maintaining the standard rigour of TGA assessment. For EBR, securing Priority Review reflects both the clinical importance of the WiSE system and the strength of the supporting evidence base.

The Priority Review pathway also signals regulatory recognition of the CRT non-responder population’s clinical need, providing additional credibility for engagement with Australian cardiology specialists, hospitals and reimbursement authorities.

Australian commercial environment

Australia’s cardiology market is well-developed, with established CRT implant volumes and a network of specialist heart failure clinics. The Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) frameworks influence reimbursement and access dynamics, although devices follow distinct funding pathways from pharmaceuticals.

EBR’s Australian launch will involve engagement with cardiology specialists, hospital procurement teams and private health insurers. Existing relationships with key opinion leaders in the cardiology community will support adoption alongside the regulatory milestone.

Sector context: ASX cardiac and wireless MedTech

The ASX hosts a small but visible cohort of cardiac-focused MedTech companies, with EBR joined by names in cardiac monitoring, structural heart and electrophysiology. The wireless cardiac pacing thematic is differentiated and provides exposure to one of the more interesting areas of medical device innovation.

Globally, wireless cardiac pacing has been gaining attention as established lead-based systems face their inherent technical limitations. EBR’s WiSE positioning within this trend supports a credible commercial trajectory.